|
Although the genomic profiles of African American men with prostate cancer differ from those of European American men, new data show that the frequency of actionable mutations for which targeted therapies exist occurs at a comparable rate in both populations.
This indicates that African American men can still benefit from available treatments presuming therapy is equitable.
|